Clinical outcomes of transcarotid artery revascularization vs carotid endarterectomy from a large single-center experience

医学 颈动脉内膜切除术 冲程(发动机) 围手术期 血运重建 心力衰竭 内科学 心脏病学 心肌梗塞 外科 狭窄 机械工程 工程类
作者
Ali F. AbuRahma,Adrian Santini,Zachary AbuRahma,Andrew Lee,Christina Veith,Noah Dargy,Robert Cragon,Scott L. Dean,E Mattox
出处
期刊:Journal of Vascular Surgery [Elsevier BV]
标识
DOI:10.1016/j.jvs.2024.01.213
摘要

Abstract

Background

Transcarotid artery revascularization (TCAR) has been practiced as an alternative for both carotid endarterectomy (CEA) and transfemoral carotid artery stenting, specifically in high-risk patients. More recently, the Centers for Medicare and Medicaid Services expanded coverage for TCAR in standard surgical risk patients if done within the Society for Vascular Surgery Vascular Quality Initiative TCAR surveillance project. A few registry studies (primarily from the Society for Vascular Surgery Vascular Quality Initiative) compared the early and up to 1-year outcomes of TCAR vs CEA or transfemoral carotid artery stenting. There is no large single-center study that reported late clinical outcomes. The present study compares intermediate clinical outcomes of TCAR vs CEA.

Methods

This study retrospectively analyzed collected data from TCAR surveillance project patients enrolled in our institution and compare it with CEA patients done by the same providers at the same time period. The primary outcome was combined perioperative stroke/death and late stroke/death. Secondary outcomes included combined stroke, death, and myocardial infarction, cranial nerve injury (CNI), and bleeding. Propensity matching was done to analyze outcome. Kaplan-Meier analysis was used to estimate freedom from stroke, stroke/death, and ≥50% and ≥80% restenosis.

Results

We analyzed 646 procedures (637 patients) (404 CEA, 242 TCAR). There was no significant difference in the indications for carotid intervention. However, TCAR patients had more high-risk criteria, including hypertension, coronary artery disease, congestive heart failure, and renal failure. There was no significant differences between CEA vs TCAR in 30-day perioperative stroke (1% vs 2%), stroke/death rate (1% vs 3%; P = .0849), or major hematomas (2% vs 2%). The rate of CNI was significantly different (5% for CEA vs 1% for TCAR; P = .0138). At late follow-up (2 years), the rate of stroke was 1% vs 4% (P = .0273), stroke/death 8% vs 15% (P = .008), ≥80 % restenosis 0.5% vs 3% (P = .0139) for CEA patients vs TCAR patients, respectively. After matching 242 CEAs and 242 TCARs, the perioperative stroke rate was 1% for CEA vs 2% for TCAR (P = .5037), the stroke/death rate was 2% vs 3% (P = .2423), and the CNI rate was 3% vs 1% (P = .127). At late follow-up, rates of stroke were 1% for CEA vs 4% for TCAR (P = .0615) and stroke/death were 8% vs 15% (P = .0345). The rate of ≥80% restenosis was 0.9% for CEA vs 3% for TCAR (P = .099). The rates of freedom from stroke at 6, 12, 18, and 24 months for CEA vs TCAR were 99%, 99%, 99%, and 99% vs 97%, 95%, 93% and 93%, respectively (P = .0806); stroke/death were 94%, 90%, 87%, and 86% vs 93%, 87%, 76%, and 75%, respectively (P = .0529); and ≥80% restenosis were 100%, 99%, 98%, and 98% vs 97%, 95%, 93%, and 93%, respectively (P = .1132).

Conclusions

In a propensity-matched analysis, both CEA and TCAR have similar perioperative clinical outcomes. However, CEA was superior to TCAR for the rates of late stroke/death and had a somewhat lower rate of ≥80% restenosis at 2 years, but this difference was not statistically significant.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
zp560完成签到,获得积分0
刚刚
狂野的中恶完成签到,获得积分20
1秒前
uqq完成签到,获得积分10
1秒前
铲屎大王完成签到,获得积分10
1秒前
昀松完成签到,获得积分10
1秒前
我不到啊完成签到 ,获得积分10
2秒前
wulin314完成签到,获得积分10
2秒前
2秒前
卓奕雯完成签到 ,获得积分10
2秒前
不安的雅阳完成签到,获得积分10
3秒前
牛马完成签到,获得积分10
3秒前
天穹雨应助网友九顺叔采纳,获得20
4秒前
大个应助光学工程小学采纳,获得10
4秒前
nauheim发布了新的文献求助10
5秒前
铁蛋完成签到,获得积分10
5秒前
yordeabese完成签到,获得积分10
6秒前
yl发布了新的文献求助10
6秒前
彭于晏应助CUI采纳,获得10
6秒前
teeeed完成签到,获得积分10
7秒前
九湖夷上完成签到,获得积分10
7秒前
7秒前
慕青应助binglangcha采纳,获得10
7秒前
无情的翠果完成签到,获得积分10
8秒前
南漂完成签到,获得积分10
8秒前
坚强的晓博完成签到,获得积分10
8秒前
Randy完成签到,获得积分10
9秒前
两只晕虾完成签到,获得积分10
9秒前
李李完成签到,获得积分10
10秒前
拉普拉斯开始变换完成签到,获得积分10
10秒前
风中黎昕完成签到 ,获得积分10
10秒前
小小博发布了新的文献求助10
11秒前
小李完成签到,获得积分10
11秒前
乐观的水儿完成签到,获得积分10
11秒前
11秒前
司佳雨完成签到,获得积分10
11秒前
天气不错完成签到,获得积分10
11秒前
Sirius星月完成签到,获得积分10
11秒前
111完成签到,获得积分10
12秒前
12秒前
一只蓉馍馍完成签到,获得积分10
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Prompt Engineering for Clinicians: Harnessing AI in Everyday Medical Practice 600
University Physics for the Life Sciences 500
REAL-WORLD EFFICACY AND GENOMIC LANDSCAPE OF POLATUZUMA VEDOTIN-BASED FIRST-LINE THERAPY IN DIFFUSE LARGE B-CELL LYMPHOMA: A FOCUS ON TP53 MUTATIONS AND TREATMENT RESPONSE 500
Handbook of Luminescence Dating 500
Safety Pharmacology 500
《KNN基无铅压电陶瓷电学性能优化与物理机理研究》 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 计算机科学 化学工程 生物化学 物理 内科学 复合材料 催化作用 光电子学 物理化学 电极 细胞生物学 基因 遗传学
热门帖子
关注 科研通微信公众号,转发送积分 6951482
求助须知:如何正确求助?哪些是违规求助? 8635612
关于积分的说明 18310753
捐赠科研通 6393827
什么是DOI,文献DOI怎么找? 3082063
关于科研通互助平台的介绍 2127231
邀请新用户注册赠送积分活动 2058938